Aarhus University Seal / Aarhus Universitets segl

The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

Standard

The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. / Østergaard, Søren Dinesen; Foldager, Leslie; Mors, Ole; Beck, Per; Correll, Christoph U.

I: Schizophrenia Bulletin, Bind 44, Nr. Suppl_1, 01.04.2018, s. S341-S342.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

Harvard

Østergaard, SD, Foldager, L, Mors, O, Beck, P & Correll, CU 2018, 'The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia', Schizophrenia Bulletin, bind 44, nr. Suppl_1, s. S341-S342.

APA

Østergaard, S. D., Foldager, L., Mors, O., Beck, P., & Correll, C. U. (2018). The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Schizophrenia Bulletin, 44(Suppl_1), S341-S342.

CBE

Østergaard SD, Foldager L, Mors O, Beck P, Correll CU. 2018. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Schizophrenia Bulletin. 44(Suppl_1):S341-S342.

MLA

Vancouver

Østergaard SD, Foldager L, Mors O, Beck P, Correll CU. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Schizophrenia Bulletin. 2018 apr 1;44(Suppl_1):S341-S342.

Author

Østergaard, Søren Dinesen ; Foldager, Leslie ; Mors, Ole ; Beck, Per ; Correll, Christoph U. / The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. I: Schizophrenia Bulletin. 2018 ; Bind 44, Nr. Suppl_1. s. S341-S342.

Bibtex

@article{1201c3127f024176a1c0dc84663ce976,
title = "The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia",
abstract = "BackgroundA six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social withdrawal, N6=Lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) has shown promise in the measurement of symptom severity in acutely exacerbated- and chronic schizophrenia, but its validity in treatment-resistant schizophrenia remains unknown. Therefore, we tested the validity and sensitivity of PANSS-6 based on data from the clozapine phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.MethodsI) The scalability of PANSS-6 and PANSS-30 (i.e., whether all items provide unique information regarding syndrome severity) was tested by means of item response theory analysis ad modum Rasch; II) The correlation between PANSS-6 and PANSS-30 total scores was investigated by means of Spearman correlation analysis; III) The accuracy of PANSS-6 in identifying symptom remission was tested by comparing remission on PANSS-6 (score of ≤3 on each of the six PANSS-6 items) with remission according to the Andreasen criteria (score of ≤3 on the 8 PANSS items considered in the Andreasen criteria); and IV) The antipsychotic effect of clozapine was compared to that of olanzapine, risperidone and quetiapine using the “speed of change” on PANSS-6 and PANSS-30 (change in total score per day) as outcomes.ResultsWe found that I) only PANSS-6 and not PANSS-30 was scalable; II) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), III) PANSS-6 did accurately classify syndrome remission as defined by the Andreasen criteria, and IV) The only antipsychotic that resulted in improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.072 points/day; 95%CI: -0.121, -0.024) and when using PANSS-30 (speed of change: -0.201 points/day; 95%CI: -0.400, -0.002) as outcome measures.DiscussionThese findings suggest that PANSS-6 validly measures severity, remission and antipsychotic efficacy in treatment-resistant schizophrenia.",
author = "{\O}stergaard, {S{\o}ren Dinesen} and Leslie Foldager and Ole Mors and Per Beck and Correll, {Christoph U}",
year = "2018",
month = apr,
day = "1",
language = "English",
volume = "44",
pages = "S341--S342",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "Suppl_1",
note = "6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS) ; Conference date: 04-04-2018 Through 08-04-2018",

}

RIS

TY - ABST

T1 - The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

AU - Østergaard, Søren Dinesen

AU - Foldager, Leslie

AU - Mors, Ole

AU - Beck, Per

AU - Correll, Christoph U

PY - 2018/4/1

Y1 - 2018/4/1

N2 - BackgroundA six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social withdrawal, N6=Lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) has shown promise in the measurement of symptom severity in acutely exacerbated- and chronic schizophrenia, but its validity in treatment-resistant schizophrenia remains unknown. Therefore, we tested the validity and sensitivity of PANSS-6 based on data from the clozapine phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.MethodsI) The scalability of PANSS-6 and PANSS-30 (i.e., whether all items provide unique information regarding syndrome severity) was tested by means of item response theory analysis ad modum Rasch; II) The correlation between PANSS-6 and PANSS-30 total scores was investigated by means of Spearman correlation analysis; III) The accuracy of PANSS-6 in identifying symptom remission was tested by comparing remission on PANSS-6 (score of ≤3 on each of the six PANSS-6 items) with remission according to the Andreasen criteria (score of ≤3 on the 8 PANSS items considered in the Andreasen criteria); and IV) The antipsychotic effect of clozapine was compared to that of olanzapine, risperidone and quetiapine using the “speed of change” on PANSS-6 and PANSS-30 (change in total score per day) as outcomes.ResultsWe found that I) only PANSS-6 and not PANSS-30 was scalable; II) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), III) PANSS-6 did accurately classify syndrome remission as defined by the Andreasen criteria, and IV) The only antipsychotic that resulted in improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.072 points/day; 95%CI: -0.121, -0.024) and when using PANSS-30 (speed of change: -0.201 points/day; 95%CI: -0.400, -0.002) as outcome measures.DiscussionThese findings suggest that PANSS-6 validly measures severity, remission and antipsychotic efficacy in treatment-resistant schizophrenia.

AB - BackgroundA six-item version (PANSS-6: P1=Delusions, P2=Conceptual disorganization, P3=Hallucinations, N1=Blunted Affect, N4=Social withdrawal, N6=Lack of spontaneity/flow of conversation) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) has shown promise in the measurement of symptom severity in acutely exacerbated- and chronic schizophrenia, but its validity in treatment-resistant schizophrenia remains unknown. Therefore, we tested the validity and sensitivity of PANSS-6 based on data from the clozapine phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.MethodsI) The scalability of PANSS-6 and PANSS-30 (i.e., whether all items provide unique information regarding syndrome severity) was tested by means of item response theory analysis ad modum Rasch; II) The correlation between PANSS-6 and PANSS-30 total scores was investigated by means of Spearman correlation analysis; III) The accuracy of PANSS-6 in identifying symptom remission was tested by comparing remission on PANSS-6 (score of ≤3 on each of the six PANSS-6 items) with remission according to the Andreasen criteria (score of ≤3 on the 8 PANSS items considered in the Andreasen criteria); and IV) The antipsychotic effect of clozapine was compared to that of olanzapine, risperidone and quetiapine using the “speed of change” on PANSS-6 and PANSS-30 (change in total score per day) as outcomes.ResultsWe found that I) only PANSS-6 and not PANSS-30 was scalable; II) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), III) PANSS-6 did accurately classify syndrome remission as defined by the Andreasen criteria, and IV) The only antipsychotic that resulted in improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.072 points/day; 95%CI: -0.121, -0.024) and when using PANSS-30 (speed of change: -0.201 points/day; 95%CI: -0.400, -0.002) as outcome measures.DiscussionThese findings suggest that PANSS-6 validly measures severity, remission and antipsychotic efficacy in treatment-resistant schizophrenia.

M3 - Conference abstract in journal

VL - 44

SP - S341-S342

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - Suppl_1

T2 - 6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS)

Y2 - 4 April 2018 through 8 April 2018

ER -